4.7 Article

Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 65, 期 18, 页码 11985-12001

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c00523

关键词

-

资金

  1. National Natural Science Foundation of China (NSFC) [81803364, 81872743]
  2. Basic and Applied Basic Research Foundation of Guangzhou [202102020546]
  3. High-level University Construction Fund of Guangdong Province [06-410-2107213]

向作者/读者索取更多资源

This study discovered an orally bioavailable proteasome inhibitor NIC-0102 that specifically inhibits NLRP3 inflammasome activation. It also demonstrated that NIC-0102 shows potent anti-inflammatory effects on an in vivo ulcerative colitis model.
NLRP3 inflammasome activation plays a critical role in inflammation-related disorders. More small-molecule entities are needed to study the mechanism of NLRP3 inflammasome activation and to validate the efficacy and safety of the NLRP3 pathway. Herein, we report the discovery of an orally bioavailable proteasome inhibitor NIC-0102 (27) that specifically prevents NLRP3 inflammasome activation but has no effect on NLRC4 or AIM2 inflammasomes. In vitro studies revealed that NIC-0102 induced the polyubiquitination of NLRP3, interfered with the NLRP3-ASC interaction, and blocked ASC oligomerization, thereby resulting in the inhibition of NLRP3 inflammasome activation. In addition, NIC-0102 also inhibited the production of pro-IL-1 beta. Importantly, NIC-0102 showed potent anti-inflammatory effects on DSS-induced ulcerative colitis model in vivo. As a result of these studies, a potential small molecule is identified to demonstrate the possible link between the proteasome and NLRP3 pathway, which supports further exploration of potentially druggable nodes to modulate NLRP3 inflammasome activation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据